Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.
暂无分享,去创建一个
Remco Dijkman | Katia Basso | Maarten H Vermeer | K. Basso | R. Willemze | M. Vermeer | R. Dijkman | C. Tensen | Cornelis P Tensen | Rein Willemze | Juliette J Hoefnagel | Patty M Jansen | Christian Hallermann | J. Hoefnagel | C. Hallermann | P. Jansen
[1] C. Meijer,et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Kerl,et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.
[3] Y. Tsujimoto,et al. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[4] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Scarisbrick,et al. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. , 2002, The Journal of investigative dermatology.
[6] H. Kerl,et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. , 2000, Blood.
[7] B. Klein,et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma , 1997, Nature Genetics.
[8] C. Chang,et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. , 2002, Blood.
[9] Sanjay Gupta,et al. Stage-Specific Modulation of IFN-Regulatory Factor 4 Function by Krüppel-Type Zinc Finger Proteins1 , 2001, The Journal of Immunology.
[10] J. Hanfelt,et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Y. Tu,et al. Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.
[12] H Stein,et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. , 2000, Blood.
[13] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[14] R. Willemze,et al. Primary Cutaneous Large B-Cell Lymphomas of the Legs: A Distinct Type of Cutaneous B-Cell Lymphoma With an Intermediate Prognosis , 1996 .
[15] D. Rossi,et al. Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. , 2002, Human pathology.
[16] M. Seto,et al. MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) , 2002, Japanese journal of cancer research : Gann.
[17] M. Lohuizen,et al. Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice , 1989, Nature.
[18] T. Taniguchi,et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). , 1995, Nucleic acids research.
[19] T. Hirano,et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. , 1999, Immunity.
[20] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Jaffe,et al. Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] L. Staudt,et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.
[23] S. Whittaker,et al. Comparative genomic hybridization analysis of primary cutaneous B‐cell lymphomas: Identification of common genomic alterations in disease pathogenesis , 2002, Genes, chromosomes & cancer.
[24] R. Siebert,et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. , 2004, The Journal of investigative dermatology.
[25] Katia Basso,et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. , 2003, Blood.
[26] J. Fanzo,et al. Regulation of Lymphocyte Apoptosis by Interferon Regulatory Factor 4 (IRF-4) , 2003, The Journal of experimental medicine.
[27] A. Sánchez-Aguilera,et al. Cell cycle deregulation in B-cell lymphomas. , 2003, Blood.
[28] R. Warnke,et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. , 1993, Blood.
[29] N. Pimpinelli,et al. Primary cutaneous B‐cell lymphoma: A unique type of low‐grade lymphoma. Clinicopathologic and immunologic study of 83 cases , 1991, Cancer.
[30] A. Zeiher,et al. Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway , 2000, Molecular and Cellular Biology.
[31] C. Meijer,et al. Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients. , 1987, Journal of the American Academy of Dermatology.
[32] A. Berns,et al. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc , 1997, Oncogene.
[33] G. Fleuren,et al. Bcl‐2, Bcl‐6 and CD10 expression in cutaneous B‐cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance , 2003, The British journal of dermatology.
[34] R. Willemze,et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. , 1996, Archives of dermatology.
[35] H. Prince,et al. Clinical study of primary cutaneous B‐cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications , 2003, The Australasian journal of dermatology.
[36] T. Jacks,et al. Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. , 1993, Genes & development.
[37] C. Meijer,et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Grzeschik,et al. Organization and sequence of the gene encoding the human acrosin-trypsin inhibitor (HUSI-II). , 1993, Gene.
[39] S. Whittaker,et al. Absence of the t(14; 18) chromosomal translocation in primary cutaneous B‐cell lymphoma: reply from authors , 2002, The British journal of dermatology.
[40] R. Warnke,et al. Cutaneous Follicular Lymphoma , 1986, The American journal of surgical pathology.
[41] H. Ohno,et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] T. Mak,et al. Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.
[43] T. Yoshino,et al. Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. , 1992, Blood.
[44] R. Siebert,et al. Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. , 2004, The Journal of investigative dermatology.
[45] Martin Vingron,et al. Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.
[46] P. McKay,et al. Primary Cutaneous Diffuse Large B-cell Lymphoma: Prognostic Significance of Clinicopathological Subtypes , 2003, The American journal of surgical pathology.
[47] K. Becker,et al. Analysis of microarray data using Z score transformation. , 2003, The Journal of molecular diagnostics : JMD.
[48] A. Berns,et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.
[49] D. Delia,et al. Reticulohistiocytoma of the dorsum. , 1988, Journal of the American Academy of Dermatology.
[50] A. Calastretti,et al. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. , 2001, European journal of cancer.
[51] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.